Hermab 150mg Injection is a pharmaceutical product containing the active ingredient Trastuzumab. Trastuzumab is a targeted therapy, specifically a monoclonal antibody, designed to treat certain types of cancer. It works by targeting the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in some cancer cells, including certain types of breast cancer and gastric cancer. By binding to HER2, Trastuzumab inhibits the growth and proliferation of these cancer cells.
Hermab 150mg Injection is indicated for the treatment of HER2-positive breast cancer, both in early-stage and advanced stages, and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The dosage and administration of Hermab 150mg Injection should be determined by a qualified healthcare professional based on the patient’s condition and response to treatment. Common side effects may include fever, chills, nausea, vomiting, fatigue, and infusion-related reactions. Serious side effects can occur, and patients should report any unusual symptoms to their doctor immediately. Hermab 150mg Injection should be stored as per the manufacturer’s instructions, typically refrigerated, and protected from light.
